The short version of melanogenesis fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-25 and is reviewed periodically as new material appears.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
AI can be used to create sexually explicit images and videos featuring unconsenting individuals, most often celebrities. 404 Media reported the existence of a Telegram bot for generating AI videos that has a monthly audience of over 100,000 users. In 2025, the Chinese technology company Alibaba released a video generation model called Wan 2.1, which was subsequently modified to remove guardrails, allowing generation of suggestive content.
Chumming (American English from Powhatan) is the blue water fishing practice of throwing meat-based groundbait called "chum" into the water in order to lure various marine animals (usually large game fish) to a designated fishing ground, so the target animals are more easily caught by hooking or spearing. Chums typically consist of fresh chunks of fish meat with bone and blood, the scent of which attracts predatory fish, particularly sharks, billfishes, tunas and groupers. In the past, the chum contents have also been made from "offal", the otherwise rejected or unwanted parts of slaughtered animals such as internal organs.
Gastrointestinal Distress (nausea, vomiting, diarrhea, and oral ulcerations). Central Nervous System: Seizures, tremors, muscular twitching, confusion, agitation, ataxia, and hallucinations. Skin reactions Hepatotoxicity Infertility Hair Loss
in areas as specific as human rights, of which, this administration of President Castillo, is fundamentally supportive and is very committed." According to witnesses from a business meeting with the President, Castillo had no knowledge of the proposed bill and said that he would hold a meeting with the Free Peru caucus to discuss the matter. Afterward, a Free Peru parliamentarian withdrew her signature from the bill. While the bill still had enough signatures to be presented before the ordinary committee, nothing more came of it. On 23 November 2021, President Castillo criticized the media for "distorting reality" and malicious editing. This came after numerous media outlets reported that Arequipa residents called for Castillo to be impeached while he visited the city, which he claimed was not true. On 4 December 2021, Vice President Dina Boluarte announced that there would be changes in the Government, with one of them being greater communication of President Castillo and the press. Boluarte also announced that the Hall of Chroniclers of the Government Palace was reopened since 1 December 2021, which would allow accredited journalists to carry out news coverage from within the Government Palace and make it easier for journalists to reach out to the President.
== Early life and education == Strahl was born in Buffalo, New York and raised in Albuquerque, New Mexico. He moved to Chapel Hill, North Carolina in 1980 when his father went to medical school at the University of North Carolina at Chapel Hill. Strahl entered the University of North Carolina at Greensboro in 1988, where he double majored in Chemistry and Biology. Strahl joined the Department of Biochemistry at North Carolina State University and received his PhD in 1998 under the supervision of Dr. William L. Miller. At North Carolina State University, Strahl defined mechanisms for how the Follicle-Stimulating Hormone-Beta (FSHß) gene is regulated at the transcriptional level. In 1998, Strahl performed postdoctoral studies under the mentorship of Dr. C. David Allis at the University of Virginia’s Department of Biochemistry and Molecular Genetics.
Sources: en.wikipedia.org
Globally, the number of people with opioid dependence increased from 10.4 million in 1990 to 15.5 million in 2010. In 2016, the numbers rose to 27 million people who experienced this disorder. Opioid use disorders resulted in 122,000 deaths worldwide in 2015, up from 18,000 in 1990. Deaths from all causes rose from 47.5 million in 1990 to 55.8 million in 2013.
B lymphocytes (B cells), which are part of the normal immune response, are also responsible for the over-aggressive response seen in autoimmune diseases like systemic lupus erythematosus. B cells develop in the bone marrow and continue to mature peripherally in secondary lymphoid organs and in the gut. When autoimmune B cells attack the body's own tissues, they are normally destroyed by cell suicide (apoptosis). Researchers theorize that systemic lupus erythematosus is caused when autoimmune B cells proliferate and survival factors protect them from cell suicide. B-cell activating factor (BAFF), also called B-lymphocyte stimulator (BLyS), is required for the development and survival of B cells. In systemic lupus erythematosus patients, BAFF is overexpressed, which may cause autoimmune B cell proliferation and survival. Belimumab binds to BAFF and prevents it from binding to B cells. Without BAFF, B cells commit suicide and no longer contribute to the autoimmune damage of systemic lupus erythematosus. BAFF is secreted by a variety of cells: monocytes and macrophages; bone marrow stromal cells; astrocytes in certain glioblastomas; synoviocytes in rheumatoid arthritis; and salivary epithelial cells in Sjögren syndrome. It interacts with three membrane receptors on B lymphocytes:
Zinc dialkyldithiophosphates (often referred to as ZDDP) are a family of coordination compounds classified as members of transition metal dithiophosphate complexes. These compounds were introduced in the 1940s as oil additives. They are uncharged compounds, not salts. They are soluble in nonpolar solvents, and the longer-chain derivatives easily dissolve in mineral and synthetic oils used as lubricants. They come under CAS number 68649-42-3 . In aftermarket oil additives, the percentage of ZDDP ranges approximately between 2 and 15%. Zinc dithiophosphates have many names, including ZDDP, ZnDTP, and ZDP.
The proposed formation of a UN "verification mission" to monitor Cuba's adherence to a withdrawal settlement proved instrumental in persuading the South African government that it would receive a balanced agreement. The talks began progressing more smoothly after July 1988, when Carlos Aldana Escalante was appointed head of the Cuban delegation. Aldana was chief of ideological affairs and international relations for the Communist Party of Cuba; he was far better informed of foreign developments, particularly in the Soviet bloc, than many of his contemporaries. In light of Gorbachev's reforms, political developments in Eastern Europe, and the reduction of tensions between the superpowers, Aldana believed that Cuba needed to work swiftly towards normalising relations with the US. Cooperation vis-à-vis Southern Africa was seen as a natural prerequisite to better relations with Washington and possibly, a permanent bilateral dialogue. Between May and September 1988, the parties met for several rounds of talks in Cairo, New York, Geneva, and Brazzaville, but remained deadlocked on the nuances of the withdrawal timetable. The fact that there were two objectives—Namibian independence and a Cuban withdrawal—doubly aggravated the issue of timing and deadlines. In August, the Angolan, Cuban, and South African delegations signed the Geneva Protocol, which established the principles for a peace settlement in South West Africa and committed the SADF to a withdrawal from that territory. As a direct result of the Geneva Protocol, PLAN declared a ceasefire effective from 10 August.
Sources: en.wikipedia.org
== Contamination and response in 2009–2010 == On 2 December 2009, China detained three employees of Shaanxi Jinqiao Dairy Company in northwest China suspected of selling 5.25 tons of melamine-laced powdered milk to Nanning Yueqian Food Additive Company, in Guangxi. On 30 December 2009, Xinhua reported continuing problems: powder and flavouring products sold by another company involved in the original scandal–the Shanghai Panda Dairy Company–were found to contain illegal levels of melamine; the dairy was closed and three of its executives arrested. On 25 January 2010, it was reported that three food companies from Hebei, Liaoning and Shandong provinces had produced melamine tainted products in March and April 2009 and that the three companies were banned from selling products in Guizhou. On 10 February 2010 China's state council announced a food safety commission, consisting of three vice premiers and a dozen minister-level officials, to address the nation's food regulatory problems. The group aims to improve government coordination and enforcement and to solve systemic food safety problems. As part of its ongoing effort to find and destroy any melamine-tainted milk remaining on the market, the Chinese government announced that it was recalling 170 tons of powdered milk laced with the industrial chemical which was supposed to have been destroyed or buried in 2008 but has recently found to have been repackaged and placed back into the marketplace.
Several new methods for DNA sequencing were developed in the mid to late 1990s and were implemented in commercial DNA sequencers by 2000. Together these were called the "next-generation" or "second-generation" sequencing (NGS) methods, in order to distinguish them from the earlier methods, including Sanger sequencing. In contrast to the first generation of sequencing, NGS technology is typically characterized by being highly scalable, allowing the entire genome to be sequenced at once. Usually, this is accomplished by fragmenting the genome into small pieces, randomly sampling for a fragment, and sequencing it using one of a variety of technologies, such as those described below. An entire genome is possible because multiple fragments are sequenced at once (giving it the name "massively parallel" sequencing) in an automated process. NGS technology has tremendously empowered researchers to look for insights into health, anthropologists to investigate human origins, and is catalyzing the "Personalized Medicine" movement. However, it has also opened the door to more room for error. There are many software tools to carry out the computational analysis of NGS data, often compiled at online platforms such as CSI NGS Portal, each with its own algorithm. Even the parameters within one software package can change the outcome of the analysis. In addition, the large quantities of data produced by DNA sequencing have also required development of new methods and programs for sequence analysis.
=== Randomness of mutations === There is a widespread assumption that mutations are (entirely) "random" with respect to their consequences (in terms of probability). This was shown to be wrong as mutation frequency can vary across regions of the genome, with such DNA repair- and mutation-biases being associated with various factors. For instance, Monroe and colleagues demonstrated that—in the studied plant (Arabidopsis thaliana)—more important genes mutate less frequently than less important ones. They demonstrated that mutation is "non-random in a way that benefits the plant". Additionally, previous experiments typically used to demonstrate mutations being random with respect to fitness (such as the Fluctuation Test and Replica plating) have been shown to only support the weaker claim that those mutations are random with respect to external selective constraints, not fitness as a whole.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.